疫苗巨头收入暴跌

药智网
24 Feb

2021年,Moderna凭借新冠产品收入暴增2200%,达到185亿美元,位列全球制药企业营收榜第19位。但红利来得快,去得也快。在新冠疫情的潮水退去后,Moderna迎来了“生存考验年”。尽管公司通过成本削减稳住了现金流,但核心业务萎缩、新产品商业化遇阻以及研发管线的不确定性,使其仍深陷亏损泥潭。图片来源:摄图网1收入“腰斩”,巨亏36亿美元根据Moderna财报,2024年公司全年营收32...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10